Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 10/20 | 0.46 |
| ▸ | MAOA | P21397 | 4/20 | 0.41 |
| ▸ | CALML3 | P27482 | 4/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | SDHA | P31040 | 1/20 | 0.41 |
| ▸ | F10 | P00742 | 5/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5367062 | 0.99 | MAOB (0.46) | MAOBMAOACALML3LMNAPTGS1 | |
| SCHEMBL5391040 | 0.90 | MAOB (0.46) | MAOBMAOACALML3LMNAPTGS1 | |
| SCHEMBL14580213 | 0.84 | MAOB (0.53) | MAOBMAOACALML3LMNAPTGS1 | |
| SCHEMBL5378767 | 0.84 | MAOB (0.43) | MAOBMAOACALML3LMNAPTGS1 | |
| SCHEMBL14580215 | 0.84 | MAOB (0.51) | MAOBMAOACALML3LMNAPTGS1 | |
| SCHEMBL5389507 | 0.83 | CALML3 (0.45) | MAOBMAOACALML3LMNAPTGS1 | |
| SCHEMBL14593671 | 0.82 | MAOB (0.51) | MAOBMAOACALML3LMNAPTGS1 | |
| SCHEMBL5388149 | 0.81 | MAOA (0.64) | MAOBMAOACALML3LMNAPTGS1 | |
| SCHEMBL5381931 | 0.81 | MAOB (0.49) | MAOBMAOACALML3LMNAPTGS1 | |
| SCHEMBL5390487 | 0.80 | MAOB (0.50) | MAOBMAOACALML3LMNAPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040059120-A1 | Novel heterocyclic compounds having antibacterial activity: Process for their preparation and pharmaceutical compositions containing them | DR. REDDY'S LABORATORIES INC. | 2004-03-25 | — | — | US | claimed |
| US-20030065175-A1 | Novel heterocyclic compounds having antibacterial activity: process for their preparation and pharmaceutical compositions containing them | DR. REDDY'S RESEARCH FOUNDATION | 2003-04-03 | — | — | US | claimed |
| US-7183301-B2 | Heterocyclic compounds having antibacterial activity: process for their preparation and pharmaceutical compositions containing them | DR. REDDY'S RESEARCH FOUNDATION (IN) | 2007-02-27 | — | — | US | disclosed |
| US-7160912-B2 | Heterocyclic compounds having antibacterial activity: process for their preparation and pharmaceutical compositions containing them | DR.REDDY'S LABORATORIES LTD. (IN) | 2007-01-09 | — | — | US | disclosed |
| US-20070004712-A1 | Salts of novel heterocyclic compounds having antibacterial activity | DR. REDDY'S LABORATORIES LTD. (IN) | 2007-01-04 | — | — | US | disclosed |
| US-20060293315-A1 | Intermediates of novel heterocyclic compounds having antibacterial activity and process for their preparation | DR. REDDY'S LABORATORIES LTD. (IN) | 2006-12-28 | — | — | US | disclosed |
| US-7030148-B2 | Heterocyclic compounds having antibacterial activity: process for their preparation and pharmaceutical compositions containing them | DR. REDDY'S RESEARCH FOUNDATION (IN) | 2006-04-18 | — | — | US | disclosed |
| US-20040059120-A1 | Novel heterocyclic compounds having antibacterial activity: Process for their preparation and pharmaceutical compositions containing them | DR. REDDY'S LABORATORIES INC. | 2004-03-25 | — | — | US | disclosed |
| US-20030065175-A1 | Novel heterocyclic compounds having antibacterial activity: process for their preparation and pharmaceutical compositions containing them | DR. REDDY'S RESEARCH FOUNDATION | 2003-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004712-A1 | Salts of novel heterocyclic compounds having antibacterial activity | OXA1L, LSS, MRPL21 | MAOB 1728/4885MAOA 2014/4885CALML3 3867/4885 |
| US-20030065175-A1 | Novel heterocyclic compounds having antibacterial activity: process for their preparation and pharmaceutical compositions containing them | MRPL21, Q6ZSR9, ZYX | MAOB 364/4885MAOA 460/4885CALML3 3452/4885 |
| US-20060293315-A1 | Intermediates of novel heterocyclic compounds having antibacterial activity and process for their preparation | CYP51A1, OXA1L, LSS | MAOB 692/4885MAOA 896/4885CALML3 4640/4885 |
| US-20040059120-A1 | Novel heterocyclic compounds having antibacterial activity: Process for their preparation and pharmaceutical compositions containing them | MRPL21, Q6ZSR9, ZYX | MAOB 348/4885MAOA 456/4885CALML3 3458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.